The global maternal mental health market size is calculated at USD 14.03 billion in 2024, grew to USD 18.10 billion in 2025 and is anticipated to reach around USD 179.71 billion by 2034, poised to grow at a CAGR of 29.05% between 2024 and 2034. The North America maternal mental health market size is calculated at USD 6.03 billion in 2024 and is estimated to grow at a fastest CAGR of 29.20% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Maternal Mental Health Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Maternal Mental Health Market, by Disease Indication, 2024-2034
8.1.1. Postpartum Depression
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Dysthymia
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Maternal Mental Health Market, by Treatment, 2024-2034
9.1.1. Interpersonal Psychotherapy
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Antidepressants
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.1.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.2.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.5.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Treatment (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Disease Indication (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Treatment (2021-2034)
11.1. Sage Therapeutics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Happify Health
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sonder Mind
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Maven Clinic
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Wildflower Health
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hims and Hers
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medela LLC
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Clue
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Happy Mom
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Postpartum Support International
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample